EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent of -$1.80 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent · last filed 2024-11-07
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2024-09-30 was -$1.80M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2024-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2024-03-31 was $200.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2023-12-31 was -$1.80M, a 128.13% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2023 was -$11.00M, a 146.03% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2022 was $23.90M, a 99.17% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2021 was $12.00M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2020 was -$20.20M.
| Period end | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | -$1.80M 10-Q · filed 2024-11-07 | -$1.80M derived: sum of 2 quarters · filed 2024-11-07 | -$1.60M 10-Q · filed 2024-11-07 | -$3.40M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $200.00K 10-Q · filed 2024-08-07 | -$1.60M derived: sum of 3 quarters · filed 2024-08-07 | -$3.80M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-03-31 | $200.00K 10-Q · filed 2024-05-02 | -$1.60M derived: sum of 2 quarters · filed 2024-05-02 | -$3.80M derived: sum of 3 quarters · filed 2024-11-07 | -$8.20M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$4.00M derived: sum of 2 quarters · filed 2024-11-07 | -$8.40M derived: sum of 3 quarters · filed 2024-11-07 | -$11.00M 10-K · filed 2024-03-08 | |
| 2023-09-30 | -$2.20M 10-Q · filed 2024-11-07 | -$6.60M derived: sum of 2 quarters · filed 2024-11-07 | -$9.20M 10-Q · filed 2024-11-07 | -$2.90M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$4.40M 10-Q · filed 2024-08-07 | -$7.10M 10-Q · filed 2024-08-07 | -$700.00K derived: sum of 3 quarters · filed 2024-08-07 | $2.40M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | -$2.70M 10-Q · filed 2024-05-02 | $3.70M derived: sum of 2 quarters · filed 2024-05-02 | $6.80M derived: sum of 3 quarters · filed 2024-05-02 | $11.90M derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $9.50M derived: sum of 2 quarters · filed 2024-03-08 | $14.60M derived: sum of 3 quarters · filed 2024-03-08 | $23.90M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $3.10M 10-Q · filed 2023-12-11 | $8.20M derived: sum of 2 quarters · filed 2023-12-11 | $17.50M 10-Q · filed 2023-12-11 | $26.00M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-06-30 | $5.10M 10-Q · filed 2023-08-09 | $14.40M 10-Q · filed 2023-08-09 | $22.90M derived: sum of 3 quarters · filed 2024-03-08 | $24.50M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-03-31 | $9.30M 10-Q · filed 2023-05-10 | $17.80M derived: sum of 2 quarters · filed 2024-03-08 | $19.40M derived: sum of 3 quarters · filed 2024-03-08 | $21.10M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2021-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $10.10M derived: sum of 2 quarters · filed 2024-03-08 | $11.80M derived: sum of 3 quarters · filed 2024-03-08 | $12.00M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $1.60M 10-Q · filed 2022-11-09 | $3.30M derived: sum of 2 quarters · filed 2022-11-09 | $3.50M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $1.70M 10-Q · filed 2022-08-02 | $1.90M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | $200.00K 10-Q · filed 2022-04-29 | ||||
| 2020-12-31 | -$20.20M 10-K/A · filed 2023-12-11 | -$19.80M 10-K · filed 2022-02-25 | |||
| 2019-12-31 | -$5.30M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |